Second Course of Radium-223 Demonstrates Promising Results in mCRPC

Article

According to results of a phase I/II study, men with metastatic castration-resistant prostate cancer who received a second course of radium-223 (Xofigo) experienced minimal hematologic toxicity and low radiographic bone progression rates.

Prostate Cancer

Prostate Cancer

According to results of a phase I/II study, men with metastatic castration-resistant prostate cancer (mCRPC) who received a second course of radium-223 (Xofigo) experienced minimal hematologic toxicity and low radiographic bone progression rates.

In the study, 29 of 44 patients (66%) received the full course of 6 injections. Median time to total alkaline phosphatase was not reached. Median time to PSA progression was 2.2 months.

Median time from end of initial radium-223 treatment was 6 months. At 12.8 months maximum follow-up, median radiographic progression-free survival (rPFS) was 9.9 months.

Thirteen patients (30%) experienced rPFS events. One patient had confirmed radiographic bone progression, 8 had soft tissue or visceral tumor progression, 2 had radiographic progression with incomplete documentation, and 2 died without evidence of radiographic disease progression. Among 8 patients with soft tissue or visceral tumor progression, 1 received concomitant hormonal therapy with abiraterone acetate (Zytiga) during treatment.

The study was designed to assess the safety of re-treatment with up to 6 radium-223 injections, administered at 4-week intervals, to mCRPC patients who previously received a full course of radium-223. Additional efficacy objectives included radiographic disease progression, total alkaline phosphatase, PSA responses, overall survival, symptomatic skeletal events (SSEs), and pain outcomes.

A total of 59 patients from 7 countries enrolled in the trial. Adults with pathologically confirmed mCRPC who had previously completed a full course of radium-223 with no evidence of bone progression during initial treatment were eligible for inclusion. Patients had either radiologic or biochemical/clinical progression after initial treatment.

Patients with treatment-related serious or grade 3/4 adverse events (AEs) during or after initial treatment that did not resolve or led to treatment discontinuation were ineligible. Patients with visceral metastases ≥1 cm in diameter measured ≤30 days from treatment start or who received chemotherapy after their initial course of radium-223 were also excluded.

All patients had received at least 2 prior hormonal regimens, and 73% developed disease progression following prior therapy with abiraterone or enzalutamide (Xtandi) and eventually developed disease progression. Twenty patients (44%) had at least 1 prior chemotherapy regimen.

Four patients discontinued prematurely due to radiographic progression, 6 for clinical progression, 3 for an AE not associated with clinical progression, and 2 for patient request.

Five (11%) patients died and 8 (18%) experienced first SSEs. Median OS, time to first SSE, and SSE-free survival were not reached. Five (14%) of 36 evaluable patients experienced pain progression. After 2 years of follow-up, 28 (64%) patients died, and the median OS was 24.4 months.

Forty-one (93%) patients experienced at least one any-grade TEAE. There were no grade 4/5 hematologic TEAEs, and no cases of myelofibrosis, aplastic anemia, or other forms of myelosuppression of any grade reported. The most common nonhematologic TEAEs were fatigue (27%), nausea (25%), and diarrhea (20%). Those AEs were all grade 1/2, except for a single incidence of grade 3 nausea.

Eighteen patients (41%) experienced a grade 3 TEAE including hypertension (11%) and anemia (5%).

Thirteen patients (30%) experienced treatment-emergent serious AEs, though only a single case of dehydration was considered treatment-related. Twenty-two patients (50%) experienced treatment-related TEAEs, including grade 3 anemia and thrombocytopenia (5%). Investigators said neutrophil, platelet, and hemoglobin values were relatively unchanged over time.

One patient experienced a treatment-related TEAE (thrombocytopenia) leading to dose delay or discontinuation. One patient experienced treatment-related TEAEs (fatigue and influenza-like illness) leading to permanent discontinuation.

Of the 5 patient deaths, 1 occurred during the treatment period. Two deaths were attributed to disease progression, 2 were attributed to AEs not associated with clinical disease progression, and 1 cause of death was unknown.

Reference:

Sartor O, Heinrich D, Mariados N, et al. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.Ann Oncol.2017; 28(10):2464-2471.

Related Videos
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Related Content